Clinical Studies on Itraconazole

Koji Takaki; Yoshiro Sawae; Kaoru Okada; Nobuyuki Shimono; Hiroyasu Misumi

doi:10.3314/jjmm.32.273

Clinical Studies on Itraconazole

Koji Takaki, Yoshiro Sawae, Kaoru Okada, Nobuyuki Shimono, Hiroyasu Misumi

General Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We performed clinical studies on itraconazole, a new triazole antifungal agent. Four patients suffering from candidemia, pulmonary aspergillosis, oral thrush, and urinary tract infection due to Trichosporon cutaneum were treated with itraconazole at a single daily dose of 100-200 mg for 9-31 days. Clinical response was good in all patients. Bacteriological effect was eradicated in 2 cases, diminished in one and unknown in one. No side effect was observed and there were no abnormal laboratory findings. A suspected case of pulmonary cryptococcosis tolerated long-term administration of itraconazole at a daily dose of 100-150 mg for 198 days without observable adverse reactions.

Original language	English
Pages (from-to)	273-278
Number of pages	6
Journal	Nippon Ishinkin Gakkai Zasshi
Volume	32
Issue number	4
DOIs	https://doi.org/10.3314/jjmm.32.273
Publication status	Published - 1991

All Science Journal Classification (ASJC) codes

Microbiology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3314/jjmm.32.273

Cite this

@article{14c67a10c9054613a97cd971e536f040,

title = "Clinical Studies on Itraconazole",

abstract = "We performed clinical studies on itraconazole, a new triazole antifungal agent. Four patients suffering from candidemia, pulmonary aspergillosis, oral thrush, and urinary tract infection due to Trichosporon cutaneum were treated with itraconazole at a single daily dose of 100-200 mg for 9-31 days. Clinical response was good in all patients. Bacteriological effect was eradicated in 2 cases, diminished in one and unknown in one. No side effect was observed and there were no abnormal laboratory findings. A suspected case of pulmonary cryptococcosis tolerated long-term administration of itraconazole at a daily dose of 100-150 mg for 198 days without observable adverse reactions.",

author = "Koji Takaki and Yoshiro Sawae and Kaoru Okada and Nobuyuki Shimono and Hiroyasu Misumi",

year = "1991",

doi = "10.3314/jjmm.32.273",

language = "English",

volume = "32",

pages = "273--278",

journal = "Medical mycology journal",

issn = "2185-6486",

publisher = "Japanese Society for Medical Mycology",

number = "4",

}

TY - JOUR

T1 - Clinical Studies on Itraconazole

AU - Takaki, Koji

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

PY - 1991

Y1 - 1991

N2 - We performed clinical studies on itraconazole, a new triazole antifungal agent. Four patients suffering from candidemia, pulmonary aspergillosis, oral thrush, and urinary tract infection due to Trichosporon cutaneum were treated with itraconazole at a single daily dose of 100-200 mg for 9-31 days. Clinical response was good in all patients. Bacteriological effect was eradicated in 2 cases, diminished in one and unknown in one. No side effect was observed and there were no abnormal laboratory findings. A suspected case of pulmonary cryptococcosis tolerated long-term administration of itraconazole at a daily dose of 100-150 mg for 198 days without observable adverse reactions.

AB - We performed clinical studies on itraconazole, a new triazole antifungal agent. Four patients suffering from candidemia, pulmonary aspergillosis, oral thrush, and urinary tract infection due to Trichosporon cutaneum were treated with itraconazole at a single daily dose of 100-200 mg for 9-31 days. Clinical response was good in all patients. Bacteriological effect was eradicated in 2 cases, diminished in one and unknown in one. No side effect was observed and there were no abnormal laboratory findings. A suspected case of pulmonary cryptococcosis tolerated long-term administration of itraconazole at a daily dose of 100-150 mg for 198 days without observable adverse reactions.

UR - http://www.scopus.com/inward/record.url?scp=0026091898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026091898&partnerID=8YFLogxK

U2 - 10.3314/jjmm.32.273

DO - 10.3314/jjmm.32.273

M3 - Article

AN - SCOPUS:0026091898

VL - 32

SP - 273

EP - 278

JO - Medical mycology journal

JF - Medical mycology journal

SN - 2185-6486

IS - 4

ER -

Clinical Studies on Itraconazole

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this